Immunocytochemical Characterization of Alzheimer Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine
Figure 4
Clearing effect of established AD hallmarks by EB101 vaccine in the brains of PS1/APP transgenic mice. Transverse brain sections of 21-month-old mice of the treatment period (phase II), showing almost complete reduction of AD hallmarks after EB101 vaccine immunization compared with EB102-immunized mice and PBS control groups.